

List of Tables

<i>Table 1: Summary of structure, homology and tissue distribution of PPARs.....</i>	<i>7</i>
<i>Table 2: Available treatment for metabolic syndrome</i>	<i>10</i>
<i>Table 3: Therapeutic targets of PPAR in the metabolic syndrome.....</i>	<i>16</i>
<i>Table 4: Role of PPARs in inflammation</i>	<i>20</i>
<i>Table 5: In vitro PPAR agonistic activity of the test compounds 11a-f</i>	<i>42</i>
<i>Table 6: EC₅₀ values of selected the test compounds.....</i>	<i>43</i>
<i>Table 7: Anti-hyperglycemic activity of compound 11a in db/db mice^a</i>	<i>44</i>
<i>Table 8: In vitro PPAR agonistic activity of test compounds 20a-f and 21a-f.....</i>	<i>50</i>
<i>Table 9: EC₅₀ values of selected test compounds 20a and 21a.....</i>	<i>52</i>
<i>Table 10: Anti-hyperglycemic activity of the selected compound 20a in db/db mice^a</i>	<i>52</i>
<i>Table 11: In vitro PPAR agonistic activity of test compounds 36a-h.....</i>	<i>63</i>
<i>Table 12: In vitro PPAR agonistic activity of test compounds 44a-g.....</i>	<i>65</i>
<i>Table 13: Anti-hyperglycemic activity of the selected compound 36f in db/db mice^a</i>	<i>66</i>
<i>Table 14: In vitro PPAR agonistic activity of test compounds 50a-c.....</i>	<i>70</i>
<i>Table 15: In vitro PPAR agonistic activity of test compounds 56a-k.</i>	<i>78</i>
<i>Table 16: In vitro PPAR agonistic activity of test compounds 59a-f.....</i>	<i>81</i>
<i>Table 17: In vitro PPAR agonistic activity of test compounds 61a-e.....</i>	<i>82</i>
<i>Table 18: LPS induce endotoxemia of test compound 56i in SAM and BALB/c mice^a</i>	<i>85</i>
<i>Table 19: Pharmacokinetic parameters^a of compound 56i in S.D. rats at 10 mg/kg oral.....</i>	<i>86</i>

List of Figures

Figure 1: The functional domains of PPARs.....	3
Figure 2: Overlays of PPAR isoforms.....	6
Figure 3: Gene transcription mechanisms of PPAR.....	11
Figure 4: Inflammatory actions of PPARs: Mechanisms of transrepression.....	19
Figure 5: Chemical structures of PPAR α agonists.....	22
Figure 6: Chemical structures of PPAR γ agonists.....	24
Figure 7: Chemical structures of PPAR α/γ dual agonists.....	25
Figure 8: Chemical structures of PPAR δ agonists.....	28
Figure 9: PPAR γ/δ dual agonists.....	30
Figure 10: PPAR-pan agonists.....	31
Figure 11: Selective PPAR modulators.....	33
Figure 12: Designing PPAR-pan agonist: Introduction of structurally constrained linker.....	37
Figure 13: PPAR α/γ dual agonists possessing structurally constrained linker.....	38
Figure 14: Anti-hyperlipidemic activity of the selected compound 11a in Hamster.....	45
Figure 15: Designing PPAR-pan agonist: Bioisosteric Replacement of thiazole.....	47
Figure 16: Anti-hyperlipidemic activity of the selected compound 11a in Hamster.....	53
Figure 17: Molecular docking of Compound 20a into PPAR α (A), γ (B) and δ (C) binding pockets.....	55
Figure 18: Designing PPAR-pan agonist: Replacement of Lipophilic Part.....	57
Figure 19: Designing PPAR-pan agonist: Modification in acetic head.....	68
Figure 20: Designing PPAR δ agonist.....	74
Figure 21: EC ₅₀ of selected test compounds 56i and 56j.....	80
Figure 22: Fold induction Vs DMSO of Compound 56i.....	80
Figure 23: Anti-hyperglycemic activity of the selected compound 56i in db/db mice.....	84
Figure 24: LPS induce endotoxemia of compound 56i in SAM.....	86
Figure 25: Molecular docking of Compound 56i into PPAR α (A), γ (B) and δ (C) binding pockets.....	88